Biontech Se

This study tests a new mRNA vaccine (BNT166a) to see if it is safe and triggers a strong immune response against mpox (formerly monkeypox). About 310 healthy adults in African countries will receive either the vaccine or a placebo. The trial includes people who have never been ex…

This study is for adults with advanced solid tumors who have run out of standard treatments. It tests a new drug called BNT3212, given alone or with another drug (BNT327), to see if it is safe and can shrink tumors. The goal is to find the best dose and check for side effects in …

This study tests a new experimental drug, BNT116, for people with advanced non-small cell lung cancer. The goal is to find safe doses when given alone or with other cancer treatments. About 320 participants will take part in this early-phase trial.

This study tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with a tough-to-treat type of breast cancer (triple-negative) that has spread. About 558 participants will be randomly assigned to receive either BNT327 plus chemo or a placebo plus…

This study tests whether a new drug called BNT323 works better than standard chemotherapy for people with a certain type of advanced endometrial cancer that has returned after previous treatment. About 480 adults whose tumors have a specific marker (HER2) will be split into two g…

This early-stage study tests a new drug, BNT317, in about 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the body processes the drug and wh…

This study tests if a new drug called BNT324 works better than standard chemotherapy (docetaxel plus steroids) for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 736 men who have already tried one hormone treatment but not chemothera…

This study tests a new drug called BNT327 combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. About 1,260 participants will be enrolled globally. The goal is to see if the combination shrinks tumors and …

This study tests a new drug called BNT326, alone or with other cancer treatments, in people with advanced solid tumors that have spread or come back. The goal is to find the best dose and see if it is safe and effective. About 980 adults will take part.

This study is the first time the experimental drug BNT3214 is being tested in people. It aims to find a safe dose and see if it can shrink tumors in adults with advanced solid cancers that have not responded to other treatments. About 533 participants will take part across multip…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug combo. About 621 adults who have not yet been treated for this cancer will take part. The goal i…

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors and control the disease. About 420 adults w…

This study tests whether adding the experimental vaccine BNT113 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer caused by HPV type 16. About 350 adults whose cancer has spread or cannot be removed wil…

This early-stage trial tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The study also looks at whether the drug can shrink t…

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer that has worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and shrinks tumors. The goal is …

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to find the best dose and see if the combination can shrink tumors. About 380 participants with various types of breast can…

This study tests two experimental drugs, BNT324 and BNT327, together in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 594 adults will take part, and the focus is on safety and …

This study tests whether adding a new drug (BNT314) to an existing immunotherapy and chemotherapy can help people with advanced colorectal cancer that didn't respond to first treatment. About 482 adults with a specific type of colorectal cancer (MSS/pMMR) will receive the combina…

This study tests a new drug called BNT327 combined with chemotherapy in people with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination can shrink tumors and control the disease. About 105 adults will take part, and the study is cu…

This study tests two experimental treatments for people whose glioblastoma (a severe brain cancer) has come back after standard therapy. One group receives pumitamig alone, another gets pumitamig plus chemotherapy, and a third gets a different drug called bevacizumab. The goal is…

This early-stage study tests a lab-made antibody called BNT351 in up to 61 adults, both with and without HIV. The main goals are to check safety, measure how long the antibody stays in the blood, and see if it can lower HIV levels in people with the virus. It is a first step to s…

This study is testing a personalized cancer vaccine (RO7198457) for people with stage II or III colorectal cancer who have had surgery to remove their tumor but still have tiny traces of cancer DNA in their blood. The goal is to see if the vaccine can help prevent the cancer from…